胃间质瘤术前辅助伊马替尼治疗的临床意义

doi:10.11904/j.issn.1002-3070.2015.05.009

Abstract

Abstract: Objective Gastrointestinal stromal tumor(GIST)is a rare mesenchymal tumor from gastrointestinal tract,and surgery remains the only curative treatment.In order to improve the outcome of surgical treatment,reduce the risk of surgery,and increase the quality of life,preoperative imatinib(IM)treatment for GIST is investigated.Methods We retrospectively studied the multidisciplinary team model treatments for 8 GIST cases receiving preoperative IM treatment.The cases were prescribed IM of 400mg daily for 12 to 40 weeks and extensively followed until surgery was considered feasibleg.The clinical significance and safety profile were analyzed.Results Partial responsive rate was 62.5% in this study.There was no intolerable sever adverse effects by IM preoperative treatment.All the cases received R₀ dissection,with no intraoperative tumor rupture.The postoperative recovery was satisfied.Conclusion IM preoperative treatment brings significant clinical benefit to large stomach GISTs and cardiac region GISTs.The preoperative treatment should be monitored carefully under a multidisciplinary team.Preoperative IM treatment is an evocative treatment strategy for high risk GIST.

Key words: Gastrointestinal stromal tumor(GIST), Imatinib, Preoperative treatment, Multidisciplinary team(MDT)

CLC Number:

R735.2

PEI Wenye, ZHANG Jun, YAN Fujun, WANG Ping, ZHAO Yan. Clinical significance of preoperative imatinib therapy in stomach gastrointestinal stromal tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 424-427.

References

1 Corless CL,Barnett CM,Heinrich MC.Gastrointestinal stromal tumours:origin and molecular oncology[J].Nat Rev Cancer,2011,11(12):865-878.
2 Zaydfudim V,Okuno SH,Que FG,et al.Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors[J].J Surg Res,2012,177(2):248-254.
3 Eisenberg BL.The SSG XVIII/AIO trial:results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors[J].Am J Clin Oncol,2013,36(1):89-90.
4 Corless CL,Ballman KV,Antonescu CR,et al.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor:the ACOSOG Z9001 trial[J].J Clin Oncol,2014,32(15):1563-1570.
5 Lang I,Hitre E,Horvath Z,et al.Case 3.Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy[J].J Clin Oncol,2003,21(18):3538-3540.
6 Fujimoto Y,Akiyoshi T,Konishi T,et al.Laparoscopic sphincter-preserving surgery(intersphincteric resection)after neoadjuvant imatinib treatment for gastrointestinal stromal tumor(GIST)of the rectum[J].Int J Colorectal Dis,2014,29(1):111-116.
7 Wang D,Zhang Q,Blanke CD,et al.Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors:long-term follow-up results of Radiation Therapy Oncology Group 0132[J].Ann Surg Oncol,2012,19(4):1074-1080.
8 Pandey R,Kochar R.Management of gastrointestinal stromal tumors:looking beyond the knife.An update on the role of adjuvant and neoadjuvant imatinib therapy[J].J Gastrointest Cancer,2012,43(4):547-552.
9 Koontz MZ,Visser BM,Kunz PL.Neoadjuvant imatinib for borderline resectable GIST[J].J Natl Compr Canc Netw,2012,10(12):1477-1482.
10 Blesius A,Cassier PA,Bertucci F,et al.Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial[J].BMC Cancer,2011,11:72.
11 Kang GH,Son MW,Han SW,et al.Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection[J].J Korean Surg Soc,2012,82(2):120-124.
12 Eisenberg BL,Harris J,Blanke CD,et al.Phase II trial of neoadjuvant/adjuvant imatinib mesylate(IM)for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor(GIST):early results of RTOG 0132/ACRIN 6665[J].J Surg Oncol,2009,99(1):42-47.
13 Andtbacka RH,Ng CS,Scaife CL,et al.Surgical resection of gastrointestinal stromal tumors after treatment with imatinib[J].Ann Surg Oncol,2007,14(1):14-24.
14 Bednarski BK,Araujo DM,Yi M,et al.Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors[J].Ann Surg Oncol,2014,21(8):2499-2505.
15 CSCO胃肠间质瘤专家委员会.中国胃肠间质瘤诊断治疗共识(2013年版)[J].临床肿瘤学杂志,2013,18(11):1025-1032.
16 Jakob J,Mussi C,Ronellenfitsch U,et al.Gastrointestinal stromal tumor of the rectum:results of surgical and multimodality therapy in the era of imatinib[J].Ann Surg Oncol,2013,20(2):586-592.
17 Tielen R,Verhoef C,van Coevorden F,et al.Surgical management of rectal gastrointestinal stromal tumors[J].J Surg Oncol,2013,107(4):320-323.

[1]	MENG Hai,DU Guanxiang,ZHU Liling,TANG Qiyun. The expression of WEE1 in gastric cancer and its influence on prognosis of patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 239-243.
[2]	LIU Jiayin,YAN Feihu,ZHANG Yanqiao. Genetic susceptibility of gastric cancer with single nucleotide polymorphisms(SNPs)of apoptotic genes - caspase-3 and caspase-7 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 250-255.
[3]	ZHANG Bao, ZHENG Zhichao. Research progress in lymph nodes dissection of advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 78-81.
[4]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[5]	LIU Yu,WANG Zian. Prognostic factors of postoperative survival in patients with primary gastrointestinal malignant lymphoma and the predictive value of TNM staging for long-term survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 315-319.
[6]	YAO Qiang, WANG Kuan, XUE Yingwei. Expression of SRC1 in gastric cancer and its prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 97-102.
[7]	ZHANG Chunhui, LIU Xia, XU Jingjing, ZHOU Yanhua, ZHAO Juan, LI Zhiwei, ZHANG Yanqiao. Clinicopathological features and survival analysis in 633 cases of gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 396-404.
[8]	ZHANG Xi ,CHEN Li ,XUE Yingwei. Prognostic value of CEA and CA19-9 expression in peripheral blood of patients with advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 342-347.
[9]	LI Enjiu, HU Didi, GONG Zhijun, QING Dujv, LIU Hong, LI Fei. The diagnostic and prognostic value of serum pepsinogen combined with Ca724 in the patients with gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 18-22.
[10]	CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.
[11]	MAO Wei, CHEN Qingjuan, SI Xiaomin, ZHANG Xiao, JIANG Cheng. Alpha-fetoprotein-high-producing hepatoid adenocarcinoma of the stomach:A case report and literature review [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 39-42.
[12]	LI Rudong, HOU Jiachen, CUI Xiaohan, WANG Xvdong. Progress in diagnosis and treatment of stomach hepatoid adenocaecinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 53-56.
[13]	PENG Wenmiao,ZHANG Zhimin,HU Meng,YU Lifang,ZHANG Bicheng,RAO Zhiguo,QIN Chuanrong. Construction and screening of RPL23-siRNA interference fragments [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 487-491.
[14]	XU Jun, ZHANG Enyong, LUO Tianhang, XUE Xuchao, CUI Hangtian, FANG Guoen. The clinicopathologic factors analysis of early mixed signet ring cell in gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 414-419.
[15]	PANG Rui,XUE Yingwei. The research and clinical application of gastric carcinoma with infiltration distance [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 314-320.

Clinical significance of preoperative imatinib therapy in stomach gastrointestinal stromal tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments